(Total Views: 530)
Posted On: 11/26/2018 6:00:28 PM
Post# of 11803
Decision Diagnostics (OTC: DECN) CEO Keith Berman discusses the company’s products targeting the $25 billion global diabetes monitoring market, and the company’s path to achieving $100 million+ revenues within next 2 years.
http://www.wallstreetreporter.com/2018/11/dec...ng-market/
(NO log-in or subscription required)
http://www.wallstreetreporter.com/2018/11/dec...ng-market/
(NO log-in or subscription required)
(2)
(0)
